Savene 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
1 issued on 
Decision 
Issued2 / 
amended 
on 
Information 
affected3 
IA/0039/G 
This was an application for a group of variations. 
18/03/2019 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are 
issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD 
is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
  
 
 
 
 
 
 
                                                
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
T/0038 
Transfer of Marketing Authorisation 
21/11/2018 
11/01/2019 
SmPC, 
Labelling and 
PL 
PSUSA/1001/
Periodic Safety Update EU Single assessment - 
04/10/2018 
n/a 
PRAC Recommendation - maintenance 
201802 
dexrazoxane 
II/0036 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
26/07/2018 
11/01/2019 
SmPC, 
new quality, preclinical, clinical or pharmacovigilance 
data 
Labelling and 
PL 
IA/0035 
B.II.e.1.b.3 - Change in immediate packaging of the 
08/02/2018 
11/01/2019 
SmPC and 
finished product - Change in type/addition of a new 
Annex II 
container - Deletion of an immediate packaging 
container without a complete deletion of a strength or 
pharmaceutical form 
II/0034/G 
This was an application for a group of variations. 
12/10/2017 
15/11/2017 
SmPC, Annex 
II, Labelling 
and PL 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
Savene  
EMA/CHMP/533498/2019 
Page 2/14 
  
  
 
 
 
 
 
 
 
 
 
 
 
PSUSA/1001/
Periodic Safety Update EU Single assessment - 
26/10/2017 
n/a 
PRAC Recommendation - maintenance 
201702 
dexrazoxane 
II/0031 
B.I.b.z - Change in control of the AS - Other variation 
08/12/2016 
n/a 
IA/0032/G 
This was an application for a group of variations. 
17/10/2016 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IA/0030/G 
This was an application for a group of variations. 
20/04/2016 
n/a 
B.II.e.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Addition of a new specification 
parameter to the specification with its corresponding 
test method 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect the 
product information 
IB/0029 
B.II.b.3.a - Change in the manufacturing process of 
14/04/2016 
n/a 
the finished or intermediate product - Minor change in 
Savene  
EMA/CHMP/533498/2019 
Page 3/14 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the manufacturing process 
IB/0027/G 
This was an application for a group of variations. 
09/12/2015 
n/a 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
Savene  
EMA/CHMP/533498/2019 
Page 4/14 
  
  
 
 
 
 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.i - Change in the specification parameters 
and/or limits of the finished product - Ph. Eur. 2.9.40 
uniformity of dosage units is introduced to replace the 
currently registered method, either Ph. Eur. 2.9.5 or 
Savene  
EMA/CHMP/533498/2019 
Page 5/14 
  
  
Ph. Eur. 2.9.6 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
II/0025 
B.I.z - Quality change - Active substance - Other 
29/10/2015 
n/a 
variation 
IB/0028/G 
This was an application for a group of variations. 
16/10/2015 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure (including 
replacement or addition) 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure (including 
replacement or addition) 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
Savene  
EMA/CHMP/533498/2019 
Page 6/14 
  
  
 
 
 
 
 
 
 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IA/0026/G 
This was an application for a group of variations. 
21/08/2015 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where batch 
control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where batch 
control/testing takes place 
IAIN/0024 
C.I.8.a - Introduction of or changes to a summary of 
01/07/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the PSMF 
location 
IAIN/0023/G 
This was an application for a group of variations. 
30/04/2015 
11/03/2016 
Annex II and PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
Savene  
EMA/CHMP/533498/2019 
Page 7/14 
  
  
 
 
 
 
 
 
 
 
 
 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - Not 
including batch control/testing 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - Not 
including batch control/testing 
Savene  
EMA/CHMP/533498/2019 
Page 8/14 
  
  
 
IB/0022 
C.I.z - Changes (Safety/Efficacy) of Human and 
26/03/2015 
11/03/2016 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
PSUSA/1001/
Periodic Safety Update EU Single assessment - 
23/10/2014 
12/01/2015 
SmPC and PL 
Please refer to dexrazoxane - PSUSA 10001 EPAR:  Scientific 
201402 
dexrazoxane 
conclusions and grounds recommending the variation of the 
terms of the marketing authorisation. 
IAIN/0021 
C.I.8.a - Introduction of or changes to a summary of 
28/11/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the PSMF 
location 
IAIN/0020 
C.I.8.a - Introduction of or changes to a summary of 
10/10/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the PSMF 
location 
IAIN/0019 
C.I.8.a - Introduction of or changes to a summary of 
06/08/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the PSMF 
location 
T/0017 
Transfer of Marketing Authorisation 
16/06/2014 
18/07/2014 
SmPC, 
Labelling and 
PL 
IAIN/0016/G 
This was an application for a group of variations. 
30/04/2014 
18/07/2014 
Annex II and PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - Not 
Savene  
EMA/CHMP/533498/2019 
Page 9/14 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
including batch control/testing 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
T/0014 
Transfer of Marketing Authorisation from SpePharm 
01/08/2013 
19/09/2013 
SmPC, 
Holding BV to Norgine BV. 
Transfer of Marketing Authorisation 
Labelling and 
PL 
N/0015 
Inclusion of Croatian Product information and Croatian 
27/08/2013 
n/a 
local representative in Annex IIIB. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
II/0013/G 
This was an application for a group of variations. 
21/06/2012 
20/07/2012 
SmPC, 
-to change the immediate packaging for the Savene 
diluent from 500 ml PE bags to 500 ml glass bottles  
-to change the manufacturer of Savene diluent, the 
suppliers of the packaging components for the diluent 
and the site responsible for Savene diluent batch 
control 
-to change the specifications and composition of 
Savene diluent and to introduce changes to analytical 
Labelling and 
PL 
Savene  
EMA/CHMP/533498/2019 
Page 10/14 
  
  
 
 
 
 
 
 
 
 
 
 
methods used in the control of the same and 
-to modify the reconstitution procedure for Savene 
powder. 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.II.b.2.a - Change to batch release arrangements 
and quality control testing of the FP - Replacement or 
addition of a site where batch control/testing takes 
place 
B.II.a.3.b.1 - Changes in the composition (excipients) 
of the finished product - Other excipients - Any minor 
adjustment of the quantitative composition of the 
finished product with respect to excipients 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure (including 
replacement or addition) 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure (including 
replacement or addition) 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure (including 
replacement or addition) 
C.I.4 - Variations related to significant modifications of 
the SPC due in particular to new quality, pre-clinical, 
clinical or pharmacovigilance data 
Savene  
EMA/CHMP/533498/2019 
Page 11/14 
  
  
 
B.II.e.1.b.2 - Change in immediate packaging of the 
finished product - Type of container - Sterile medicinal 
products and biological/immunological medicinal 
products 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change outside 
the approved specifications limits range 
R/0012 
Renewal of the marketing authorisation. 
19/05/2011 
18/07/2011 
SmPC, Annex 
Based on the review of the available information the CHMP is 
II, Labelling 
of the opinion that the quality, the safety and the efficacy of 
and PL 
Savene continues to be adequately and sufficiently 
demonstrated and considers that the benefit/risk profile of 
this medicinal product continues to be favourable. The CHMP 
therefore recommended that the Savene Marketing 
Authorisation can be renewed with unlimited validity. 
IA/0010/G 
This was an application for a group of variations. 
16/02/2011 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where batch 
control/testing takes place 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer of the finished 
product, including quality control sites (excluding 
manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
Savene  
EMA/CHMP/533498/2019 
Page 12/14 
  
  
 
 
 
 
 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.a - Change to batch release arrangements 
and quality control testing of the FP - Replacement or 
addition of a site where batch control/testing takes 
place 
N/0009 
Minor change in labelling or package leaflet not 
23/09/2010 
n/a 
PL 
connected with the SPC (Art. 61.3 Notification) 
T/0007 
Transfer of Marketing Authorisation from TopoTarget 
02/06/2010 
06/07/2010 
SmPC, Annex 
A/S to SpePharm Holding BV. 
Transfer of Marketing Authorisation 
II, Labelling 
and PL 
IA/0008 
B.II.b.2.b.1 - Change to batch release arrangements 
25/05/2010 
n/a 
Annex II and PL 
and quality control testing of the FP - Not including 
batch control/testing 
IA/0006 
IA_38_a_Change in test procedure of finished product 
24/06/2008 
n/a 
- minor change to approved test procedure 
IA/0005 
IA_28_Change in any part of primary packaging 
13/05/2008 
n/a 
material not in contact with finished product 
N/0004 
Minor change in labelling or package leaflet not 
11/02/2008 
n/a 
connected with the SPC (Art. 61.3 Notification) 
N/0003 
Minor change in labelling or package leaflet not 
28/08/2007 
n/a 
connected with the SPC (Art. 61.3 Notification) 
PL 
PL 
Savene  
EMA/CHMP/533498/2019 
Page 13/14 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0002 
Minor change in labelling or package leaflet not 
04/04/2007 
n/a 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0001 
IA_08_b_01_Change in BR/QC testing - repl./add. 
14/08/2006 
n/a 
Annex II and PL 
manuf. responsible for BR - not incl. BC/testing 
Savene  
EMA/CHMP/533498/2019 
Page 14/14 
  
  
 
 
 
 
  
